Virtual reality intervention alleviates dyspnoea in patients recovering from COVID-19 pneumonia.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
25
10
2022
accepted:
08
08
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Immersive virtual reality (iVR)-based digital therapeutics are gaining clinical attention in the field of pain management. Based on known analogies between pain and dyspnoea, we investigated the effects of visual respiratory feedback on persistent dyspnoea in patients recovering from coronavirus disease 2019 (COVID-19) pneumonia. We performed a controlled, randomised, single-blind, crossover proof-of-concept study (feasibility and initial clinical efficacy) to evaluate an iVR-based intervention to alleviate dyspnoea in patients recovering from COVID-19 pneumonia. Included patients reported persistent dyspnoea (≥5 on a 10-point scale) and preserved cognitive function (Montreal Cognitive Assessment score >24). Assignment was random and concealed. Patients received synchronous (intervention) or asynchronous (control) feedback of their breathing, embodied Study enrolment was open between November 2020 and April 2021. 26 patients were enrolled (27% women; median age 55 years, interquartile range (IQR) 18 years). Data were available for 24 of 26 patients. The median rating on a 7-point Likert scale of breathing comfort improved from 1 (IQR 2) at baseline to 2 (IQR 1) for synchronous feedback, but remained unchanged at 1 (IQR 1.5) for asynchronous feedback (p<0.05 between iVR conditions). Moreover, 91.2% of all patients were satisfied with the intervention (p<0.0001) and 66.7% perceived it as beneficial for their breathing (p<0.05). Our iVR-based digital therapy presents a feasible and safe respiratory rehabilitation tool that improves breathing comfort in patients recovering from COVID-19 infection presenting with persistent dyspnoea. Future research should investigate the intervention's generalisability to persistent dyspnoea with other aetiologies and its potential for preventing chronification.
Sections du résumé
Background
UNASSIGNED
Immersive virtual reality (iVR)-based digital therapeutics are gaining clinical attention in the field of pain management. Based on known analogies between pain and dyspnoea, we investigated the effects of visual respiratory feedback on persistent dyspnoea in patients recovering from coronavirus disease 2019 (COVID-19) pneumonia.
Methods
UNASSIGNED
We performed a controlled, randomised, single-blind, crossover proof-of-concept study (feasibility and initial clinical efficacy) to evaluate an iVR-based intervention to alleviate dyspnoea in patients recovering from COVID-19 pneumonia. Included patients reported persistent dyspnoea (≥5 on a 10-point scale) and preserved cognitive function (Montreal Cognitive Assessment score >24). Assignment was random and concealed. Patients received synchronous (intervention) or asynchronous (control) feedback of their breathing, embodied
Results
UNASSIGNED
Study enrolment was open between November 2020 and April 2021. 26 patients were enrolled (27% women; median age 55 years, interquartile range (IQR) 18 years). Data were available for 24 of 26 patients. The median rating on a 7-point Likert scale of breathing comfort improved from 1 (IQR 2) at baseline to 2 (IQR 1) for synchronous feedback, but remained unchanged at 1 (IQR 1.5) for asynchronous feedback (p<0.05 between iVR conditions). Moreover, 91.2% of all patients were satisfied with the intervention (p<0.0001) and 66.7% perceived it as beneficial for their breathing (p<0.05).
Conclusion
UNASSIGNED
Our iVR-based digital therapy presents a feasible and safe respiratory rehabilitation tool that improves breathing comfort in patients recovering from COVID-19 infection presenting with persistent dyspnoea. Future research should investigate the intervention's generalisability to persistent dyspnoea with other aetiologies and its potential for preventing chronification.
Identifiants
pubmed: 38020572
doi: 10.1183/23120541.00570-2022
pii: 00570-2022
pmc: PMC10658613
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2023.
Déclaration de conflit d'intérêts
Conflict of interest: S. Cardin and O.A. Kannape were employees of MindMaze SA at the time of the study. No MindMaze SA products were used in this study. T. Similowski reports grants from Lungpacer Inc.; consulting fees from ADEP Assistance, AstraZeneca France, Chiesi France, KPL consulting, Lungpacer Inc., Novartis France, TEVA France and Vitalaire; and support for attending meetings and/or travel from Novartis France, all outside the submitted work. O. Blanke is member of the board and shareholder of MindMaze SA, and is founder and shareholder of Metaphysiks SA. The remaining authors have no conflicts to disclose.
Références
Am J Respir Crit Care Med. 2012 Feb 15;185(4):435-52
pubmed: 22336677
Lancet Respir Med. 2021 Feb;9(2):129
pubmed: 33453162
NPJ Digit Med. 2018 Jun 13;1:22
pubmed: 31304304
Psychophysiology. 2020 Aug;57(8):e13564
pubmed: 32162704
Eur Respir J. 2020 Aug 13;:
pubmed: 32817258
Biol Psychol. 2022 May;171:108329
pubmed: 35452780
BMJ Glob Health. 2021 Sep;6(9):
pubmed: 34580069
Eur Respir J. 2017 May 25;49(5):
pubmed: 28546269
JMIR Ment Health. 2019 Jan 31;6(1):e11973
pubmed: 30702436
Curr Opin Support Palliat Care. 2019 Sep;13(3):200-210
pubmed: 31306187
Trends Cogn Sci. 2016 Mar;20(3):162-164
pubmed: 26750512
Eur Respir J. 2019 Jan 17;53(1):
pubmed: 30655454
Pain. 2021 Jun 1;162(6):1641-1649
pubmed: 33259460
Eur Respir J. 2020 Aug 6;56(2):
pubmed: 32299853
Eur Respir J. 2018 Mar 1;51(2):
pubmed: 29496732
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33303540
Eur Respir J. 2015 Jun;45(6):1681-91
pubmed: 25792641
Respir Physiol Neurobiol. 2014 Nov 1;203:68-74
pubmed: 25194692
JAMA Intern Med. 2020 Oct 1;180(10):1306-1314
pubmed: 32804188
Neurology. 2017 Oct 31;89(18):1894-1903
pubmed: 28986411
J Pain Symptom Manage. 2008 Nov;36(5):451-60
pubmed: 18495412
Eur Respir J. 2022 Nov 24;60(5):
pubmed: 36202418
Sci Rep. 2017 Aug 30;7(1):9990
pubmed: 28855723
Pain. 2021 Feb 1;162(2):325-331
pubmed: 32868750
MMWR Morb Mortal Wkly Rep. 2020 Sep 11;69(36):1250-1257
pubmed: 32915166
Respir Physiol Neurobiol. 2009 May 30;167(1):53-60
pubmed: 18706531
Eur Respir J. 2017 Sep 27;50(3):
pubmed: 28954773
Eur Respir J. 2017 Sep 12;50(3):
pubmed: 28899937
Eur Heart J. 2008 Mar;29(6):816-24
pubmed: 18310669
Am Rev Respir Dis. 1992 Nov;146(5 Pt 1):1222-5
pubmed: 1443874
Trends Cogn Sci. 2019 May;23(5):377-388
pubmed: 30826212
Neuroimage. 2009 Oct 15;48(1):200-6
pubmed: 19527787
J Med Internet Res. 2021 Feb 22;23(2):e26292
pubmed: 33484240